Dorart brings experience partnering with high-level executives to understand and address their strategic business needs, having held high-visibility roles in both industry and consulting. He previously worked as a Consultant in ZS Associates’ Strategy & Advisory practice, where he provided guidance to pharmaceutical and biotechnology companies of all stages on a range of strategy issues, including corporate and portfolio strategy, mergers and acquisitions, and performance transformations. Dorart created and implemented data-driven strategies to help clients avoid the most common pitfalls of M&A and pursue only those opportunities that maximize stakeholder value. He also worked with COVID-19 vaccine manufacturers to design transformational programs that delivered performance improvements across the gamut of operational levers, including cost, capital efficiency, value and access, and international presence.

Prior to joining ZS, Dorart was a Business Development & Licensing Manager at Endo Pharmaceuticals, where he was responsible for executing strategic transactions to drive inorganic pipeline growth, generate cost synergies, and fuel expansion into novel therapeutic areas. Dorart completed seven transactions with a combined value of $1B USD during his time at Endo, including, notably, the acquisition of BioSpecifics in October 2020.